<DOC>
	<DOCNO>NCT01565720</DOCNO>
	<brief_summary>This study design evaluate repeat dos isavuconazole cardiac repolarization healthy adult subject . Eligible subject randomize one four treatment group confine 17 day include pre-dosing day . Moxifloxacin give active control last dosing day healthy subject one four group . All treatment , except moxifloxacin dose , double-blinded ( neither subject study doctor know treatment assignment ) . Subjects undergo continuous ECGs three study day . ECGs , vital sign , blood draw obtain throughout study safety ass amount study drug body .</brief_summary>
	<brief_title>Study Effect Repeat Doses Isavuconazole Cardiac Repolarization</brief_title>
	<detailed_description />
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Subject must weigh least 45 kg body mass index 1830 kg/m2 If female , subject agree sexual abstinence , surgically sterile , postmenopausal use medically acceptable doublebarrier method prevent pregnancy agree continue use method study two week end study . Female subject must lactate pregnant document negative pregnancy test Screening Day 3 If male , subject agree sexual abstinence , surgically sterile , use medically acceptable method prevent pregnancy agree continue use method study two week end study The subject 's clinical laboratory test result Screening Day 3 within normal limit abnormal result consider clinically significant The subject sit systolic blood pressure 90 140 mmHg , inclusive diastolic blood pressure 50 90 mmHg , inclusive Screening Day 3 The subject good venous access The subject previous history clinically significant gastrointestinal , neurological , renal , hepatic , pulmonary , metabolic , cardiovascular , psychiatric , endocrine , hematological disorder disease , malignancy exclude nonmelanoma skin cancer medical condition would preclude participation study The subject evidence cardiac conduction abnormalities The subject history unexplained syncope , cardiac arrest , unexplained cardiac arrhythmia , torsade de pointes , structural heart disease , family history Long QT syndrome Short QT syndrome The subject potassium , calcium , magnesium level clinical laboratory 's low limit normal The subject history consume 14 unit alcoholic beverage per week , history alcohol abuse within past 2 year prior Screening , positive screen alcohol Screening Day 3 . ( NOTE : one unit = 12 ounce beer , 4 ounce wine 1 ounce spirits/hard liquor . ) The subject history drug , chemical , substance abuse within past 2 year prior Screening positive test Screening Day 3 drug abuse The subject use tobaccocontaining product nicotinecontaining product within 3 month prior Screening The subject treatment prescription drug complementary alternative medicine within 14 day prior Screening , overthecounter medication within 7 day prior Screening ( exception acetaminophen 2 grams/day ) The subject anticipate inability abstain caffeine alcohol 48 hour prior Day 3 throughout duration study The subject anticipate inability abstain grapefruit , Seville oranges , star fruit , product contain item 72 hour prior Day 3 throughout duration study The subject has/had febrile illness symptomatic , viral , bacterial ( include upper respiratory infection ) , fungal ( noncutaneous ) infection within 7 day prior Day 3 The subject vaccinate within last 30 day prior Screening The subject positive test hepatitis C antibody hepatitis B surface antigen Screening know history human immunodeficiency virus The subject know suspected hypersensitivity quinolone antibiotic history tendonitis and/or liver function abnormality relate quinolone antibiotic treatment The subject know suspected hypersensitivity isavuconazole , azole class compound , component study drug The subject receive experimental agent within 30 day five halflives , whichever longer , prior Screening The subject significant blood loss , donate one unit ( 450 mL ) blood receive transfusion blood blood product within 60 day donate plasma within 7 day prior Day 3 The subject condition , opinion investigator , preclude subject 's participation trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Isavuconazole</keyword>
	<keyword>Healthy Volunteers</keyword>
	<keyword>BAL8557</keyword>
</DOC>